BR112018067731A2 - coagonistas de glucagon e glp-1 para o tratamento de obesidade - Google Patents

coagonistas de glucagon e glp-1 para o tratamento de obesidade

Info

Publication number
BR112018067731A2
BR112018067731A2 BR112018067731A BR112018067731A BR112018067731A2 BR 112018067731 A2 BR112018067731 A2 BR 112018067731A2 BR 112018067731 A BR112018067731 A BR 112018067731A BR 112018067731 A BR112018067731 A BR 112018067731A BR 112018067731 A2 BR112018067731 A2 BR 112018067731A2
Authority
BR
Brazil
Prior art keywords
glp
glucagon
coagonists
obesity treatment
obesity
Prior art date
Application number
BR112018067731A
Other languages
English (en)
Portuguese (pt)
Inventor
Ulrich Jermutus Lutz
Petrone Marcella
Aleksandra Bednarek Maria
Ambery Philip
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of BR112018067731A2 publication Critical patent/BR112018067731A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
BR112018067731A 2016-03-10 2017-03-10 coagonistas de glucagon e glp-1 para o tratamento de obesidade BR112018067731A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662306121P 2016-03-10 2016-03-10
PCT/EP2017/055679 WO2017153575A1 (en) 2016-03-10 2017-03-10 Glucagon and glp-1 co-agonists for the treatment of obesity

Publications (1)

Publication Number Publication Date
BR112018067731A2 true BR112018067731A2 (pt) 2019-01-08

Family

ID=58266629

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018067731A BR112018067731A2 (pt) 2016-03-10 2017-03-10 coagonistas de glucagon e glp-1 para o tratamento de obesidade

Country Status (19)

Country Link
US (3) US10676517B2 (https=)
EP (1) EP3426284B1 (https=)
JP (2) JP7237590B6 (https=)
KR (2) KR20220150416A (https=)
CN (1) CN108697769A (https=)
AR (1) AR107890A1 (https=)
AU (2) AU2017229530B2 (https=)
BR (1) BR112018067731A2 (https=)
CA (1) CA3015922A1 (https=)
EA (1) EA201891946A1 (https=)
ES (1) ES2983409T3 (https=)
IL (1) IL261528B2 (https=)
MX (1) MX2018010640A (https=)
MY (1) MY191321A (https=)
NZ (1) NZ746784A (https=)
SG (2) SG11201806342SA (https=)
TW (1) TWI793069B (https=)
WO (1) WO2017153575A1 (https=)
ZA (1) ZA201806637B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3139613A1 (en) * 2019-05-21 2020-11-26 Medimmune Limited Cyclodextrin based injectable coformulations of sglt2 inhibitors and incretin peptides
EA202290107A1 (ru) 2019-07-01 2022-03-29 Медиммун Лимитед Фармацевтические композиции на основе пептидов, являющихся коагонистами глюкагона и glp-1
KR102812908B1 (ko) 2019-08-19 2025-05-28 일라이 릴리 앤드 캄파니 인크레틴 유사체의 제조 방법
JP2023505126A (ja) * 2019-12-03 2023-02-08 メディミューン，エルエルシー 肥満症の処置のためのグルカゴン及びｇｌｐ－１のコアゴニストを使用する組合せ治療
AR120714A1 (es) 2019-12-18 2022-03-09 Lilly Co Eli Análogos de incretina y sus usos
TW202140061A (zh) 2020-01-10 2021-11-01 英商梅迪繆思有限公司 用於治療２型糖尿病中的慢性腎病和糖尿病性腎病的升糖素及ｇｌｐ－１協同促效劑
CN115397455A (zh) * 2020-01-16 2022-11-25 上海仁会生物制药股份有限公司 Glp-1给药方案
CN113493503B (zh) * 2020-04-08 2022-08-05 浙江道尔生物科技有限公司 一种肠促胰岛素类似物及其制备方法和用途
KR20230005289A (ko) 2020-04-24 2023-01-09 베링거 인겔하임 인터내셔날 게엠베하 지방 간 질환 및 지방간염의 치료에서 장시간-작용성 glp-1/글루카곤 수용체 작용제로서 글루카곤 유사체
CA3201539A1 (en) * 2020-12-07 2022-06-16 Vyjayanthi Krishnan Therapeutic regimens and methods for lowering blood glucose and or body weight using glp-1r and gcgr balanced agonists
KR20230004135A (ko) * 2021-06-30 2023-01-06 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도
KR20240043778A (ko) 2021-07-30 2024-04-03 베링거 인겔하임 인터내셔날 게엠베하 장시간-작용하는 glp1/글루카곤 수용체 작용제를 위한 용량 용법
US20230374096A1 (en) * 2022-05-19 2023-11-23 Vault Bioventures, Inc. Obesity treatment and prevention methods
CN115975057B (zh) * 2023-03-16 2023-05-16 杭州信海医药科技有限公司 一种可妥度肽的固相合成方法
KR20260022948A (ko) 2023-06-09 2026-02-20 썬 파마슈티컬 인더스트리스 리미티드 Glp-1/gip 이중 수용체 작용제, glp-1/gcg 이중 수용체 작용제, 및 glp-1/gip/gcg 삼중 수용체 작용제
KR20250067206A (ko) 2023-11-07 2025-05-15 주식회사 천농바이오푸드 대사성 질환의 예방, 개선 또는 치료 효과를 갖는 채소 추출복합물 및 이의 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
SI2173890T1 (sl) 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
FR2932484B1 (fr) 2008-06-16 2010-06-18 Sanofi Aventis Nouveaux derives de pyrroloindole inhibiteurs d'hsp90, compositions les contenant et utilisation
AR072160A1 (es) 2008-06-17 2010-08-11 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
AU2010272944B2 (en) * 2009-07-13 2015-11-19 Zealand Pharma A/S Acylated glucagon analogues
KR20120123443A (ko) 2010-01-27 2012-11-08 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
CA2812951A1 (en) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Llc Engineered polypeptides having enhanced duration of action
WO2012088379A2 (en) * 2010-12-22 2012-06-28 Marcadia Biotech, Inc. Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
DK2694095T3 (en) * 2011-04-05 2018-05-28 Longevity Biotech Inc COMPOSITIONS COMPREHENSIVE GLUCAGON ANALOGS AND METHODS FOR PREPARING AND USING THE SAME
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
TWI617574B (zh) * 2012-12-11 2018-03-11 梅迪繆思有限公司 用於治療肥胖之升糖素與ｇｌｐ－１共促效劑
AU2013366692B2 (en) * 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists

Also Published As

Publication number Publication date
KR20180120739A (ko) 2018-11-06
AU2020202381A1 (en) 2020-04-30
AR107890A1 (es) 2018-06-28
ZA201806637B (en) 2019-07-31
KR102460198B1 (ko) 2022-10-31
JP7237590B6 (ja) 2023-03-28
IL261528B2 (en) 2023-09-01
US10676517B2 (en) 2020-06-09
KR20220150416A (ko) 2022-11-10
EP3426284B1 (en) 2024-05-08
CA3015922A1 (en) 2017-09-14
SG11201806342SA (en) 2018-08-30
IL261528A (en) 2018-10-31
EP3426284A1 (en) 2019-01-16
WO2017153575A1 (en) 2017-09-14
NZ746784A (en) 2022-11-25
IL261528B1 (en) 2023-05-01
TW201733613A (zh) 2017-10-01
EA201891946A1 (ru) 2019-04-30
TWI793069B (zh) 2023-02-21
SG10202109721PA (en) 2021-10-28
CN108697769A (zh) 2018-10-23
US20220041681A1 (en) 2022-02-10
JP7237590B2 (ja) 2023-03-13
US20190185537A1 (en) 2019-06-20
ES2983409T3 (es) 2024-10-23
JP2019510014A (ja) 2019-04-11
MY191321A (en) 2022-06-15
JP2023011864A (ja) 2023-01-24
AU2017229530B2 (en) 2020-05-07
AU2017229530A1 (en) 2018-10-25
US20200354426A1 (en) 2020-11-12
MX2018010640A (es) 2019-06-13

Similar Documents

Publication Publication Date Title
BR112018067731A2 (pt) coagonistas de glucagon e glp-1 para o tratamento de obesidade
JOP20200119A1 (ar) مركبات مساعد مشترك من gip وglp-1
UA118558C2 (uk) Пептидна сполука
BR112016022465A2 (pt) agonistas de receptores de glp-1/glucagon duplo peptídicos derivados de exendina-4
PH12019501216A1 (en) New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists
CR20160582A (es) Composición para tratar diabetes, que contienen un conjugado de análogo de insulina de acción prolongada y un conjugado de péptido insulinotrópico de acción prolongada
SV2017005594A (es) Compuestos co-agonistas de glucagon y glp-1
BR112019011144A2 (pt) compostos como agonistas peptídicos de receptor de glp1/glucagon/gip
UY35548A (es) Péptidos terapéuticos para el tratamiento de trastornos metabólicos.
MX2016010854A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de un antagonista de il-4r.
EA201690606A1 (ru) Аналоги глюкагона
BR112017025000A2 (pt) tratamento de hipoglicemia pós-bariátrica com exendina (9-39)
MX2016013244A (es) Derivados de exendina-4 como agonistas peptidicos duales del receptor de glp-1/glucagon.
MX2015013948A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
BR112017018954A2 (pt) uso de forma mutante de proteína ras e método para tratar câncer
BR112018077457A2 (pt) composição farmacêutica para evitar ou tratar hiperinsulinismo congênito e seu método, hipoglicemia e seu método, síndrome metabólica e seu método e peptídeo isolado
CL2013003454A1 (es) Composicion farmacéutica para prevenir o tratar diabetes que comprende un conjugado de insulina de accion prolongada y un conjugado de peptido insulinotropico de accion prolongada.
HK1220383A1 (zh) 用於治疗肥胖症的聚乙二醇化的胰高血糖素和glp-1共激动剂
MX2016013248A (es) Agonistas duales del receptor de glp-1/glucagon derivados de exendina-4.
BR112017009584A2 (pt) tratamento de retinite pigmentosa com n-acetilcisteína amida
CL2017002031A1 (es) Formulación en polvo nasal para el tratamiento de hipoglicemia
GT201700224A (es) Proteína de unión a rgma y su uso
MX2017008569A (es) Derivados de glucagon con estabilidad mejorada.
CL2015003343A1 (es) Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.
MX2016016210A (es) Metodos para el tratamiento de diabetes tipo 1 utilizando anticuerpos antagonistas del receptor de glucagon.

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122022025367-9 PROTOCOLO 870220116322 EM 12/12/2022 16:41.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2822 DE 04/02/2025.